Linked Life Data

20400961

Source:http://linkedlifedata.com/resource/pubmed/id/20400961

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-5-7
pubmed:abstractText
Autoimmune diseases are common and debilitating, but their severe manifestations could be reduced if biomarkers were available to allow individual tailoring of potentially toxic immunosuppressive therapy. Gene expression-based biomarkers facilitating such tailoring of chemotherapy in cancer, but not autoimmunity, have been identified and translated into clinical practice. We show that transcriptional profiling of purified CD8(+) T cells, which avoids the confounding influences of unseparated cells, identifies two distinct subject subgroups predicting long-term prognosis in two autoimmune diseases, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a chronic, severe disease characterized by inflammation of medium-sized and small blood vessels, and systemic lupus erythematosus (SLE), characterized by autoantibodies, immune complex deposition and diverse clinical manifestations ranging from glomerulonephritis to neurological dysfunction. We show that the subset of genes defining the poor prognostic group is enriched for genes involved in the interleukin-7 receptor (IL-7R) pathway and T cell receptor (TCR) signaling and those expressed by memory T cells. Furthermore, the poor prognostic group is associated with an expanded CD8(+) T cell memory population. These subgroups, which are also found in the normal population and can be identified by measuring expression of only three genes, raise the prospect of individualized therapy and suggest new potential therapeutic targets in autoimmunity.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1546-170X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
586-91, 1p following 591
pubmed:dateRevised
2010-7-6
pubmed:meshHeading
pubmed-meshheading:20400961-Antibodies, Antineutrophil Cytoplasmic, pubmed-meshheading:20400961-Autoimmune Diseases, pubmed-meshheading:20400961-Autoimmunity, pubmed-meshheading:20400961-CD8-Positive T-Lymphocytes, pubmed-meshheading:20400961-Cohort Studies, pubmed-meshheading:20400961-Dose-Response Relationship, Drug, pubmed-meshheading:20400961-Gene Expression, pubmed-meshheading:20400961-Humans, pubmed-meshheading:20400961-Immunosuppressive Agents, pubmed-meshheading:20400961-Inflammation, pubmed-meshheading:20400961-Interleukin-7, pubmed-meshheading:20400961-Lupus Erythematosus, Systemic, pubmed-meshheading:20400961-Prognosis, pubmed-meshheading:20400961-Receptors, Antigen, T-Cell, pubmed-meshheading:20400961-Signal Transduction, pubmed-meshheading:20400961-T-Lymphocytes, pubmed-meshheading:20400961-Vasculitis
pubmed:year
2010
pubmed:articleTitle
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease.
pubmed:affiliation
Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Cambridge, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't